HealthQuad Leads INR 117 Cr Investment in Beta Drugs for Minority Stake The Panchkula-based pharmaceutical manufacturer aims to use the fresh funds to accelerate its growth and aspires to be among the top five oncology companies in India over the next five years.

By BIZ Experiences Staff

You're reading BIZ Experiences India, an international franchise of BIZ Experiences Media.

Freepik

Beta Drugs, a vertically integrated oncology-focused pharmaceutical company, has raised INR 117 crore in primary capital from HealthQuad Fund II (HealthQuad), alongside a Singapore-based investment fund and a private wealth management firm, in exchange for a minority stake.

The funding will drive Beta Drugs' global expansion and bolster its operational capabilities. "Their investment and expertise will play a pivotal role in accelerating our growth journey as we strive to position ourselves among the top five oncology companies in India over the next five years," said Rahul Batra, Chairman and Managing Director of Beta Drugs.

Founded in 2005, Beta Drugs boasts a comprehensive portfolio covering chemotherapy, targeted therapies, hormonal treatments, and supportive care.

The company has established a strong domestic presence and expanded into over 46 international markets, with accreditations from regulatory authorities in regions such as Brazil and the EU. Remarkably, Beta Drugs claims that it was the first Indian company to introduce oncology drugs in suspension form, demonstrating its commitment to innovation.

HealthQuad's Partner Ajay Mahipal highlighted the firm's confidence in Beta Drugs' potential: "With its strong manufacturing and R&D capabilities, Beta Drugs is well-positioned to enhance affordability for middle- and lower-income segments while improving access in tier II and III cities. Their new product launches, expanding export markets, and experienced leadership team position the company for substantial growth and value creation."

HealthQuad, a healthcare transformation fund, has a robust portfolio that spans AI, data analytics, diagnostics, and pharma distribution. Its support is expected to amplify Beta Drugs' market impact and product reach.

O3 Capital acted as the exclusive advisor for the transaction, with DSK Legal, Universal Legal, and Desai and Diwanji providing legal counsel.
BIZ Experiences Staff

BIZ Experiences Staff

Editor

For more than 30 years, BIZ Experiences has set the course for success for millions of BIZ Experiencess and small business owners. We'll teach you the secrets of the winners and give you exactly what you need to lay the groundwork for success.

Most Popular

See all
Business Ideas

70 Small Business Ideas to Start in 2025

We put together a list of the best, most profitable small business ideas for BIZ Experiencess to pursue in 2025.

By Eve Gumpel
Starting a Business

How to Develop the Mindset for a Billion-Dollar Success, According to Raising Cane's Founder

Todd Graves was turned down by every bank in town when he started. Here, he sits down to share his mentality on success, leadership and building a billion-dollar brand.

By Jason Feifer
Data & Recovery

We Found Four of the Top Alternatives to Dropbox That Don't Have Monthly Subscription Fees

All last for life, and not one of them is more than $200.

By BIZ Experiences Store
Business News

Here Are the 10 Jobs AI Is Most Likely to Automate, According to a Microsoft Study

These careers are most likely to be affected by generative AI, based on data from 200,000 conversations with Microsoft's Copilot chatbot.

By Sherin Shibu
Starting a Business

These Brothers Started a Business to Improve an Everyday Task. They Made Their First Products in the Garage — Now They've Raised Over $100 Million.

Coulter and Trent Lewis had an early research breakthrough that helped them solve for the right problem.

By Amanda Breen
News and Trends

Reliance Retail Launches FMCG Brand 'Independence' In Gujarat

Independence includes diverse categories such as staples, processed foods, beverages, among other daily essentials

By Shrabona Ghosh